Table 5

Summary of clinical trials of IL-12 in patients with hematological malignancies

First author (ref. no.)Study phaseTherapyNo. of patientsDisease targetRoute of IL-12 administrationIL-12 dose (ng/kg) and scheduleCR + PR
Rook (9)IIL-1210CTCLSC or intralesional50–300, twice weekly50%
Robertson (12)IIL-1212Post-ASCT lymphoid malignancyIV30–250, daily× 5 every 21 daysN/A
Ansell (7)IIL-12+ rituximab43B-cell NHLSC30–500, twice weekly69%
Younes (this study)IIIL-1242NHL and HDIV or SC250 (IV), daily× 5 every 21 days; or 500 (SC), twice weeklyNHL: 21%, HD: 0%
  • Abbreviations: CTCL, cutaneous T-cell lymphoma; SC, subcutaneous; ASCT, autologous stem cell transplantation; IV, intravenous; N/A, not available.